Literature DB >> 7964688

Cholinergic and peptidergic systems in PSP.

F Javoy-Agid1.   

Abstract

PSP is associated with a widespread cholinergic deficit likely corresponding to a loss in cholinergic neurons. The cholinergic damage dramatically affects the basal ganglia and specific cell groups of the mesencephalon and pons. This provides an anatomically defined basis for motor and supranuclear oculomotor syndromes characteristic of PSP. Unlike Alzheimer's disease and Parkinson's disease with dementia, the disease is not associated with a marked cholinergic deficiency in the cerebral cortex. Various peptides are present at normal concentrations in extrapyramidal and limbic subcortical areas in brains of patients with PSP. Of particular interest, is somatostatin, the levels of which are subnormal in cerebral cortex of patients with dementia of Alzheimer' or Parkinson's disease type.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964688     DOI: 10.1007/978-3-7091-6641-3_16

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  5 in total

1.  In vitro characterization of [3H]VAT in cells, animal and human brain tissues for vesicular acetylcholine transporter.

Authors:  Qianwa Liang; Sumit Joshi; Hui Liu; Yanbo Yu; Haiyang Zhao; Tammie L S Benzinger; Joel S Perlmutter; Zhude Tu
Journal:  Eur J Pharmacol       Date:  2021-10-07       Impact factor: 4.432

2.  Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.

Authors:  M Asahina; T Suhara; H Shinotoh; O Inoue; K Suzuki; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

Review 3.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

4.  Behavioral abnormalities in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Kevin Duff; Benjamin Mast; Irene Litvan
Journal:  Psychiatry Res       Date:  2013-09-12       Impact factor: 3.222

Review 5.  Neurotransmitter deficits from frontotemporal lobar degeneration.

Authors:  Alexander G Murley; James B Rowe
Journal:  Brain       Date:  2018-05-01       Impact factor: 13.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.